Adverse Reactions Associated with First-line Regimens in Patient Initiating Antiretroviral Therapy
Overview
Authors
Affiliations
Objective: To evaluate the prevalence of adverse drug reactions (ADR) and associated factors during the use of Highly Active Antiretroviral Therapy (HAART) in patients initiating treatment.
Methods: This is a cross-sectional analysis of a prospective study conducted in three public referral services specialized in HIV/AIDS care in Belo Horizonte, Brazil. Self-reported ADR and explanatory variables were obtained from face-to-face interview and from Information Systems. Associated factors with ADR were evaluated by logistic regression in SPSS software v.22.
Results: We included 399 patients, of which 85.5% reported at least one and 72.7% up to 5 ADRs after HAART initiation. Neurological reactions were the most frequent, with self-reported ADRs being distinct according to HAART regimen used. The global model showed higher chance of ADRs among females (OR = 3.52) and illicit drug users (OR = 2.28). Lower chance of ADRs was found for patients aged > 33 years (OR = 0.37), DTG/TDF/3TC users (OR = 0.41), and higher physical domain of quality of life (OR = 0.78). The model restricted to patients using the single-tablet regimen EFV/TDF/3TC showed lower ADRs among patients with CD4+ T lymphocyte count > 200 cells/mm (OR = 0.23) and higher independence domain of quality of life (OR = 0.74). The model restricted to DTG/TDF/3TC and to other regimens showed lower ADRs with higher physical domain of quality of life (OR = 0.74 and OR = 0.55, respectively).
Conclusions: The prevalence of self-reported ADRs to first-line antiretroviral regimens was high and patients using DTG/TDF/3TC had a smaller number of ADRs. In addition to HAART regimen, sociodemographic, clinical, and quality of life characteristics were associated with ADRs.
Silva G, Mendicino C, Menezes de Padua C, Tupinambas U Einstein (Sao Paulo). 2023; 21:eAO0156.
PMID: 37255057 PMC: 10219625. DOI: 10.31744/einstein_journal/2023AO0156.
Zondi S, Naidoo P Pan Afr Med J. 2023; 42:218.
PMID: 36845236 PMC: 9949296. DOI: 10.11604/pamj.2022.42.218.32239.
HIV and Substance Use in Latin America: A Scoping Review.
Huff H, Carcamo P, Diaz M, Conklin J, Salvatierra J, Aponte R Int J Environ Res Public Health. 2022; 19(12).
PMID: 35742448 PMC: 9222977. DOI: 10.3390/ijerph19127198.
de Oliveira Franca P, Ayres L, Pimassoni L, Cerutti Junior C Int J Clin Pract. 2022; 2022:8341638.
PMID: 35685558 PMC: 9159168. DOI: 10.1155/2022/8341638.
Quality of life in individuals initiating antiretroviral therapy: a cohort study.
Pimentel G, Ceccato M, Costa J, Mendes J, Bonolo P, Silveira M Rev Saude Publica. 2020; 54:146.
PMID: 33331489 PMC: 7726918. DOI: 10.11606/s1518-8787.2020054001920.